Metformin and lactic acidosis in an Australian community setting: The Fremantle diabetes study

Medical Journal of Australia

Volumn 188, Issue 8, 2008, Pages 446-449

  Kamber, Niklaus ^a   Davis, Wendy A ^a   Bruce, David G ^a   Davis, Timothy M E ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUSTRALIA; CARDIOGENIC SHOCK; COMMUNITY CARE; DISEASE DURATION; DRUG CONTRAINDICATION; FEMALE; HUMAN; INCIDENCE; KIDNEY FAILURE; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PATIENT IDENTIFICATION; RISK ASSESSMENT; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DOSE RESPONSE; FOLLOW UP; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDY; TIME;

ACIDOSIS, LACTIC; ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; METFORMIN; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TIME FACTORS; WESTERN AUSTRALIA;

EID: 47049102313     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2008.tb01713.x     Document Type: Article

References (25)

1. Stacpoole PW, Harman EM, Curry SH, et al. Treatment of lactic acidosis with dichloroacetate. N Engl J Med 1983; 309: 390-396.
2. Holstein A, Stumvoll M. Contraindications can damage your health - is metformin a case in point? Diabetologia 2005; 48: 2454-2459.
3. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281-303.
4. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006; (1): CD002967.
5. Misbin RI, Green L, Stadel BV, et al. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998; 338: 265-266.
6. Nisbet JC, Sturtevant JM, Prins JB. Metformin and serious adverse effects. Med J Aust 2004; 180: 53-54.
7. Emslie-Smith AM, Boyle DI, Evans JM, et al. Contraindications to metformin therapy in patients with type 2 diabetes - a population-based study of adherence to prescribing guidelines. Diabet Med 2001; 18: 483-488.
8. Calabrese AT, Coley KC, DaPos SV, et al. Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. Arch Intern Med 2002; 162: 434-437.
9. Brown JB, Pedula K, Barzilay J, et al. Lactic acidosis rates in type 2 diabetes. Diabetes Care 1998; 21: 1659-1663.
10. Davis TM, Zimmet P, Davis WA, et al. Autoantibodies to glutamic acid decarboxylase in diabetic patients from a multi-ethnic Australian community: the Fremantle Diabetes Study. Diabet Med 2000; 17: 667-674.
11. Holman CD, Bass AJ, Rouse IL, Hobbs MS. Population-based linkage of health records in Western Australia: development of a health services research linked database. Aust N Z J Public Health 1999; 23: 453-459.
12. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
13. Davis TME, Davis WA, Bruce DG. Glycaemic levels triggering intensification of therapy in type 2 diabetes in the community: the Fremantle Diabetes Study. Med J Aust 2006; 184: 325-328.
14. UKPDS Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
15. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2006; 29 Suppl 1: S4-S42.
16. Solomon DH, Winkelmayer WC. Cardiovascular risk and the thiazolidinediones: déjà vu all over again? JAMA 2007; 298: 1216-1218.
17. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm. Diabetologia 2006; 49: 1711-1721.
18. Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo controlled, dose-response trial. Am J Med 1997; 103: 491-497.
19. Bailey CJ, Howlett HC. Defining the risk of lactic acidosis. In: Bailey CJ, Campbell IW, Chan JC et al, editors. Metformin: the gold standard. Chichester, UK: Wiley, 2007: 185-192.
20. Norman PE, Semmens JB, Laurvick CL, Lawrence-Brown M. Long-term relative survival in elderly patients after carotid endarterectomy: a population-based study. Stroke 2003; 34: e95-e98.
21. Bradshaw PJ, Jamrozik K, Jelfs P, Le M. Mobile Australians: a moving target for epidemiologists [letter]. Med J Aust 2000; 172: 566.
22. Roberts F, Ryan GJ. The safety of metformin in heart failure. Ann Pharmacother 2007; 41: 642-646.
23. Rachmani R, Slavachevski I, Levi Z, et al. Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. Eur J Intern Med 2002; 13: 428.
24. Gras V, Bouffandeau B, Montravers PH, Lalau JD. Effect of metformin on survival rate in experimental sepsis. Diabetes Metab 2006; 32: 147-150.
25. Eurich DT, Majumdar SR, McAlister FA, et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005; 28: 2345-2351.